1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > United States Genetic Testing Market Outlook to 2021

United States Genetic Testing Market Outlook to 2021

  • August 2015
  • -
  • Global Data
  • -
  • 110 pages

United States Genetic Testing Market Outlook to 2021

Summary

GlobalData’s new report, "United States Genetic Testing Market Outlook to 2021", provides key market data on the United States Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Genetic Testing market includes Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Genetic Testing market.
- Global corporate-level profiles of key companies operating within the United States Genetic Testing market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Danaher Corporation, Abbott Laboratories, Hologic, Inc., Cepheid, Bio-Rad Laboratories, Inc., Qiagen N.V., Transgenomic, Inc. and PerkinElmer, Inc.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table Of Contents

United States Genetic Testing Market Outlook to 2021
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Genetic Testing Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Genetic Testing Market, United States 9
3.1 Genetic Testing Market, United States, Revenue ($m), 2007-2014 9
3.2 Genetic Testing Market, United States, Revenue ($m), 2014-2021 11
3.3 Genetic Testing Market, United States, Distribution Share by Revenue ($m), 2013-2014 13
3.4 Genetic Testing Market, United States, Company Share by Revenue ($m), 2014 14
4 Overview of Key Companies in United States, Genetic Testing Market 16
4.1 F. Hoffmann-La Roche Ltd. 16
4.1.1 Company Overview 16
4.2 Siemens Healthcare 16
4.2.1 Company Overview 16
4.3 Abbott Laboratories 16
4.3.1 Company Overview 16
4.4 Danaher Corporation 17
4.4.1 Company Overview 17
4.5 Hologic, Inc. 17
4.5.1 Company Overview 17
4.6 Cepheid 17
4.6.1 Company Overview 17
4.7 Bio-Rad Laboratories, Inc. 18
4.7.1 Company Overview 18
4.8 Qiagen N.V. 18
4.8.1 Company Overview 18
4.9 Transgenomic, Inc. 18
4.9.1 Company Overview 18
4.10 PerkinElmer, Inc. 19
4.10.1 Company Overview 19
5 Genetic Testing Market Pipeline Products 20
6 Financial Deals Landscape 24
6.1 Acquisition 24
6.1.1 Quest Diagnostics May Sell itself 24
6.1.2 Amarantus BioScience Acquires DioGenix 25
6.1.3 Roche Acquires Bina Technologies 26
6.1.4 IBM Watson Invests in Pathway Genomics 27
6.1.5 PDI Acquires RedPath Integrated Pathology for USD23 Million 28
6.1.6 Veracyte Acquires Allegro Diagnostics for USD21 Million 30
6.2 Asset Transactions 31
6.2.1 Pacific Biosciences of California Acquires PacBio Technology from BGI 31
6.2.2 Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 32
6.3 Debt Offerings 34
6.3.1 Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 34
6.3.2 LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 36
6.3.3 LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 38
6.3.4 LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 40
6.3.5 LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 42
6.3.6 Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 44
6.3.7 Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 46
6.4 Equity Offerings 48
6.4.1 Trovagene Raises USD40.3 Million in Public Offering of Shares 48
6.4.2 Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 50
6.4.3 Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 51
6.4.4 Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 52
6.4.5 CombiMatrix to Raise USD3 Million in Private Placement of Warrants 54
6.4.6 CombiMatrix to Raise USD5 Million in Private Placement of Securities 56
6.4.7 Invitae Raises USD117 Million in IPO 58
6.4.8 AutoGenomics Withdraws IPO for up to USD48.7 Million 60
6.4.9 Interleukin Genetics Raises USD5 Million in Private Placement of Shares and Warrants 62
6.4.10 Exact Sciences Prices Public Offering of Shares for USD103 Million 64
6.4.11 Affymetrix to Raise USD50 Million in Private Placement of Shares 66
6.4.12 Nanosphere Terminates Private Placement of Shares for USD30 Million 67
6.4.13 Nanosphere Raises USD20 Million in Public Offering of Shares 68
6.4.14 DermTech Withdraws IPO 69
6.5 Partnerships 70
6.5.1 XIFIN Enters into Agreement with Translational Software 70
6.5.2 Cytox Enters into Joint Development Partnership with Affymetrix 71
6.5.3 Interleukin Genetics Enters into Licensing Agreement with NYU School of Medicine 72
6.5.4 Boston IVF Enters into Agreement with IviGen and iGenomix 73
6.5.5 Seattle Children's Hospital Enters into Agreement with NextGxDx 74
6.5.6 Genewiz Forms Joint Venture with Hy Labs 75
6.5.7 Biosearch Enters into Licensing Agreement with Co-Diagnostics 76
6.5.8 Merck Serono Enters into Co- Development Agreement with Illumina 77
6.5.9 WaferGen Biosystems Enters into Research Agreement with Women's College Research Institute 78
6.5.10 Genomic Vision Extends Agreement with Quest Diagnostics 79
6.5.11 Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 80
6.5.12 Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 81
6.5.13 Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 82
6.5.14 Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 83
6.5.15 Affymetrix Enters into Licensing Agreement with Peptide Groove 84
6.5.16 Reprogenetics Enters into RandD Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 85
6.5.17 NanoString Enters into Research Agreement with Brigham and Women's Hospital 86
6.5.18 Advanced Biological Labs Enters into Licensing Agreement with Mayo Medical Labs 87
6.5.19 Lucigen Enters into Agreement with Thermo Fisher Scientific 88
6.5.20 New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 89
6.5.21 Hibergene Diagnostics Enters into Licensing Agreement with Eiken for LAMP 90
6.5.22 WaferGen Biosystems Enters into Co-Development Agreement with Molecular Pathology Labs 91
6.6 Venture Financing 92
6.6.1 Rubicon Genomics Raises USD2 Million in Venture Financing 92
6.6.2 Courtagen Life Sciences Raises USD20 Million in Venture Financing 93
6.6.3 Personal Genome Diagnostics Raises USD4.3 Million in Venture Financing 95
6.6.4 Color Genomics Raises USD15 Million in Series A Financing 96
6.6.5 DxTerity Diagnostics Secures USD7.5 Million in Venture Debt Financing 97
6.6.6 DermTech Raises USD2.4 Million in Venture Financing 98
6.6.7 Claritas Genomics Raises USD15 Million in Series B Financing 99
6.6.8 Personalis Raises USD33 Million in Series C Financing 101
6.6.9 CardioDx Raises USD14 Million in Extended Series DD Venture Financing 102
6.6.10 KEW Group Raises USD16.8 Million in Venture Financing 103
6.6.11 InVitae Raises USD120 Million in Series F Venture Financing 104
6.6.12 IntegenX Secures USD10 Million in Financing 106
7 Appendix 107
7.1 Research Methodology 108
7.1.1 Coverage 108
7.1.2 Secondary Research 108
7.1.3 Primary Research 108
7.1.4 Company Share Analysis 109
7.1.5 Distribution Share Analysis 109
7.2 GlobalData Consulting 109
7.3 Contact Us 109
7.4 Disclaimer 110

1.1 List of Tables
Table 1: Genetic Testing Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 10
Table 2: Genetic Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 12
Table 3: Genetic Testing Market, United States, Distribution Share by Revenue ($m), USD Constant, 2013-2014 13
Table 4: Genetic Testing Market, United States, Company Share by Revenue ($m), USD Constant, 2014 15
Table 5: Genetic Testing Market Pipeline Products 20
Table 6: Quest Diagnostics May Sell itself 24
Table 7: Amarantus BioScience Acquires DioGenix 25
Table 8: Roche Acquires Bina Technologies 26
Table 9: IBM Watson Invests in Pathway Genomics 27
Table 10: PDI Acquires RedPath Integrated Pathology for USD23 Million 28
Table 11: Veracyte Acquires Allegro Diagnostics for USD21 Million 30
Table 12: Pacific Biosciences of California Acquires PacBio Technology from BGI 31
Table 13: Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 32
Table 14: Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 34
Table 15: LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 36
Table 16: LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 38
Table 17: LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 40
Table 18: LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 42
Table 19: Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 44
Table 20: Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 46
Table 21: Trovagene Raises USD40.3 Million in Public Offering of Share 48
Table 22: Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 50
Table 23: Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 51
Table 24: Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 52
Table 25: CombiMatrix to Raise USD3 Million in Private Placement of Warrants 54
Table 26: CombiMatrix to Raise USD5 Million in Private Placement of Securities 56
Table 27: Invitae Raises USD117 Million in IPO 58
Table 28: AutoGenomics Withdraws IPO for up to USD48.7 Million 60
Table 29: Interleukin Genetics Raises USD5 Million in Private Placement of Shares and Warrants 62
Table 30: Exact Sciences Prices Public Offering of Shares for USD103 Million 64
Table 31: Affymetrix to Raise USD50 Million in Private Placement of Shares 66
Table 32: Nanosphere Terminates Private Placement of Shares for USD30 Million 67
Table 33: Nanosphere Raises USD20 Million in Public Offering of Shares 68
Table 34: DermTech Withdraws IPO 69
Table 35: XIFIN Enters into Agreement with Translational Software 70
Table 36: Cytox Enters into Joint Development Partnership with Affymetrix 71
Table 37: Interleukin Genetics Enters into Licensing Agreement with NYU School of Medicine 72
Table 38: Boston IVF Enters into Agreement with IviGen and iGenomix 73
Table 39: Seattle Children's Hospital Enters into Agreement with NextGxDx 74
Table 40: Genewiz Forms Joint Venture with Hy Labs 75
Table 41: Biosearch Enters into Licensing Agreement with Co-Diagnostics 76
Table 42: Merck Serono Enters into Co- Development Agreement with Illumina 77
Table 43: WaferGen Biosystems Enters into Research Agreement with Women's College Research Institute 78
Table 44: Genomic Vision Extends Agreement with Quest Diagnostics 79
Table 45: Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 80
Table 46: Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 81
Table 47: Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 82
Table 48: Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 83
Table 49: Affymetrix Enters into Licensing Agreement with Peptide Groove 84
Table 50: Reprogenetics Enters into RandD Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 85
Table 51: NanoString Enters into Research Agreement with Brigham and Women's Hospital 86
Table 52: Advanced Biological Labs Enters into Licensing Agreement with Mayo Medical Labs 87
Table 53: Lucigen Enters into Agreement with Thermo Fisher Scientific 88
Table 54: New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 89
Table 55: Hibergene Diagnostics Enters into Licensing Agreement with Eiken for LAMP 90
Table 56: WaferGen Biosystems Enters into Co-Development Agreement with Molecular Pathology Labs 91
Table 57: Rubicon Genomics Raises USD2 Million in Venture Financing 92
Table 58: Courtagen Life Sciences Raises USD20 Million in Venture Financing 93
Table 59: Personal Genome Diagnostics Raises USD4.3 Million in Venture Financing 95
Table 60: Color Genomics Raises USD15 Million in Series A Financing 96
Table 61: DxTerity Diagnostics Secures USD7.5 Million in Venture Debt Financing 97
Table 62: DermTech Raises USD2.4 Million in Venture Financing 98
Table 63: Claritas Genomics Raises USD15 Million in Series B Financing 99
Table 64: Personalis Raises USD33 Million in Series C Financing 101
Table 65: CardioDx Raises USD14 Million in Extended Series DD Venture Financing 102
Table 66: KEW Group Raises USD16.8 Million in Venture Financing 103
Table 67: InVitae Raises USD120 Million in Series F Venture Financing 104
Table 68: IntegenX Secures USD10 Million in Financing 106

1.2 List of Figures
Figure 1: Genetic Testing Market, United States, Revenue ($m), USD Constant, Historic, 2007-2014 9
Figure 2: Genetic Testing Market, United States, Revenue ($m), USD Constant, Forecast, 2014-2021 11
Figure 3: Genetic Testing Market, United States, Company Share (%) 2014 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Preimplantation Genetic Diagnosis Market Analysis By Type, By Application And Segment Forecasts To 2024

Preimplantation Genetic Diagnosis Market Analysis By Type, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

Global preimplantation genetic diagnosisis market expected to reach USD 96.8 million by 2024, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the ...

Genetic Testing - Global Market Outlook (2016-2022)

Genetic Testing - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • August 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Genetic Testing market accounted for $3.5 billion in 2015 and is expected to reach $6.0 billion by 2022 growing at a CAGR of 8.2% from 2015 to 2022. Genetic tests ...

Europe Genetic Testing Market

Europe Genetic Testing Market

  • $ 3850
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The European genetic testing market accounted for USD 1.13 million in 2015 and is estimated to reach USD 1.22 billion in 2016. The market value is expected to reach USD 1.81 billion by 2021, growing at ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.